Evidence map›Paper›PMID 20718817›Full record

ArticleClinical and translational science2010

Molecular therapy drives patient-centric health care paradigms.

Scott A Waldman, Andre Terzic

Abstract read
In one paragraph

Article in Clinical and translational science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. The value proposition of molecular medicine.Clinical and translational science · 2012
    Article
  2. Widening the path to personalized medicine.Clinical and translational science · 2011
    Review
  3. Article
  4. Chronic diseases: the emerging pandemic.Clinical and translational science · 2011
    Article
  5. Clinical pharmacology at the core of translational science.Expert review of clinical pharmacology · 2011
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Scott A WaldmanDepartment of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. scott.waldman@jefferson.edu
Andre Terzic

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI DANIEL P SILVER · 1995 to 2026
$94.8M
Guanylyl Cyclase C in Blood and Colorectal CancerR01CA095026 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2003 to 2008
$5.1M
GUANYLYL CYCLASE C AS A BIOMARKER FOR COLORECTAL CANCERR01CA075123 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A. · 1998 to 2006
$5.1M
Occult lymph node metastases and racial disparities in colon cancer outcomesRC1CA146033 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WALDMAN, SCOTT A · 2009 to 2010
$997k
NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA075123NCI NIH HHS R01 CA095026NCI NIH HHS RC1 CA146033
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Global HealthDelivery of Health CareHumansMolecular Targeted TherapyPrecision Medicine

Identifiers

PMID20718817
PMCPMC2946388

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.